BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10203710)

  • 1. Where have all the T cells gone? Mechanisms of immune evasion by tumors.
    Finke J; Ferrone S; Frey A; Mufson A; Ochoa A
    Immunol Today; 1999 Apr; 20(4):158-60. PubMed ID: 10203710
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: γδ T Cells in Cancer.
    Coffelt SB; Kabelitz D; Silva-Santos B; Kuball J; Born W; Bank I
    Front Immunol; 2020; 11():602411. PubMed ID: 33329597
    [No Abstract]   [Full Text] [Related]  

  • 3. Strategies for immunotherapy of cancer.
    Melief CJ; Toes RE; Medema JP; van der Burg SH; Ossendorp F; Offringa R
    Adv Immunol; 2000; 75():235-82. PubMed ID: 10879286
    [No Abstract]   [Full Text] [Related]  

  • 4. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy: a treatment for the masses.
    Blattman JN; Greenberg PD
    Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive cell therapy: Honing that killer instinct.
    Humphries C
    Nature; 2013 Dec; 504(7480):S13-5. PubMed ID: 24352359
    [No Abstract]   [Full Text] [Related]  

  • 7. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
    Feldman SA; Assadipour Y; Kriley I; Goff SL; Rosenberg SA
    Semin Oncol; 2015 Aug; 42(4):626-39. PubMed ID: 26320066
    [No Abstract]   [Full Text] [Related]  

  • 8. γδ T cell-based anticancer immunotherapy: progress and possibilities.
    Meraviglia S; Lo Presti E; Dieli F; Stassi G
    Immunotherapy; 2015; 7(9):949-51. PubMed ID: 26569071
    [No Abstract]   [Full Text] [Related]  

  • 9. Cancer immunotherapy.
    Bender E
    Nature; 2017 Dec; 552(7685):S61. PubMed ID: 29293244
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status and future applications of cellular therapies for cancer.
    Copier J; Bodman-Smith M; Dalgleish A
    Immunotherapy; 2011 Apr; 3(4):507-16. PubMed ID: 21463192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Understanding Gamma Delta T Cell Multifunctionality - Towards Immunotherapeutic Applications.
    Gustafsson K; Herrmann T; Dieli F
    Front Immunol; 2020; 11():921. PubMed ID: 32477369
    [No Abstract]   [Full Text] [Related]  

  • 14. Adoptive cellular immunotherapy of cancer.
    Winter H; Fox BA
    Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
    [No Abstract]   [Full Text] [Related]  

  • 15. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis.
    Wakita D; Sumida K; Iwakura Y; Nishikawa H; Ohkuri T; Chamoto K; Kitamura H; Nishimura T
    Eur J Immunol; 2010 Jul; 40(7):1927-37. PubMed ID: 20397212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
    Martínez-Usatorre A; Donda A; Zehn D; Romero P
    J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy of cancer.
    Rosenberg SA
    Important Adv Oncol; 1992; ():17-38. PubMed ID: 1582673
    [No Abstract]   [Full Text] [Related]  

  • 19. Experimental vaccine strategies for cancer immunotherapy.
    Chen CH; Wu TC
    J Biomed Sci; 1998; 5(4):231-52. PubMed ID: 9691216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.
    Sivaram N; McLaughlin PA; Han HV; Petrenko O; Jiang YP; Ballou LM; Pham K; Liu C; van der Velden AW; Lin RZ
    J Clin Invest; 2019 May; 129(8):3264-3276. PubMed ID: 31112530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.